Navigation Links
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN

the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

About Bayer HealthCare

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the US, Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about clinical trial results, regulatory plans and expected timelines for alemtuzumab, including the initiation of a Phase 3 trial in MS patients and the timing thereof, and the ability to manage patient safety. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others: that final results of the clinical trial demonstrate safety and efficacy comparable to the interim data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data sa
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken ...ADHD within one week, PHILADELPHIA, Oct. 7 /PRNew...HPGY), the global specialty biopharmaceutical comp... September issue of the Journal of,Clinical Psychi...ed,Attention Deficit Hyperactivity Disorder (ADHD)...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sci...ire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. (...Inc. (NYSE: FRX ) today announced the presentatio...lotide,s safety and efficacy in 420 patients with,.... Analysis of the data,indicates that once- daily ...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aero... safety data from a Phase I trial of its Aerovant,...ty with no evidence of,local irritancy following a..., This 10 mg dose will be the highest of three do...ging study, which is scheduled to begin early,next...
(Date:10/7/2008)... 125 Patient, Prospective Randomized Placebo-Contr...Significant Improved Overall Survival., MOUNTAIN ...unoTherapeutics has now evaluated the mature Phase...ine candidate PROSTVAC(TM) that had been,obtained ...he National,Cancer Institute (NCI) in the US., Th...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 1Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 10Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 1Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 2Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 3Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 4Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 5Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 6ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 1ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 2Gender bias may affect care of people with osteoarthritis study finds 13976 1Gender bias may affect care of people with osteoarthritis study finds 13976 2
...7 - Novelos,Therapeutics, Inc. (OTCBB: NVLT), a bi... of therapeutics to treat cancer and,hepatitis, to...na-Farber/Partners Cancer Care (DF/PCC) Phase 2 tr...platinum-resistant ovarian,cancer patients. To dat...or response (assessed at least after 8 weeks / 2,c...
...m versus placebo: - 25,/ - 13 mm Hg (systolic / di...n vaccine dose and induced,antiangiotensin II anti... the Seventeenth European,Meeting on Hypertension ... and MILAN, Italy, June 17, 2007 -,Cytos Biotechno...ta,on its hypertension vaccine CYT006-AngQb at the...
Other Medicine Technology:Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 2Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ntists from the University of Cincinnati have come...ood obesity.// This issue has become an important...ety. In the spring season the researchers recruite...m in Meade County, Ky to fight childhood obesity. ...
...rding to the scientist from the Victorian Breast C...east stem cells which have undergone some mutation...ancers.// The Walter and Eliza Hall Institute res...en they found that the breast stem cells do not ex...
...w research conducted by consumer organization Whic...s contain high levels of fat, salt and sugar. Of...hecked for sugar, salt and fat content using the F...three-quarters had a high level of sugars, while a...
...recent announcements by Health Minister, Tony Abbo...ic health enemy No.1, has failed to impress AMA Pr...e initiatives to be much more forceful so that pro... The minister had announced a new ministerial t...
Other Medicine News:Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: